Ge Long Hui·2025-12-28 11:49Core Viewpoint - Fudan Zhangjiang (01349.HK) has received approval from the National Medical Products Administration for the clinical trial application of FZ-P001 sodium injection, aimed at visualizing malignant lesions in known or suspected lung cancer patients during surgery [1] Group 1: Product Development - FZ-P001 sodium injection is a new class of chemical drug independently developed by the company, characterized as an innovative photosensitizer [1] - The active component of FZ-P001 sodium is a molecule formed by the coupling of a folate receptor-targeting small molecule and a phthalocyanine photosensitizer [1] - The drug targets malignant tumor tissues that highly express folate receptor alpha (FRα) and provides fluorescence imaging in the near-infrared range [1] Group 2: Clinical Application - The company plans to utilize FZ-P001 sodium for developing intraoperative fluorescence guidance technology to indicate the residual malignant tumor tissue and margin status during surgeries [1] - The aim is to enhance the surgical resection effectiveness for related solid tumors, such as ovarian cancer and lung cancer [1] - This innovation seeks to provide a solution for precise navigation in tumor surgery, combining molecular targeting specificity with multidimensional biological sensing [1]